Recent progress of positron radionuclide labeled small molecule inhibitors of prostate specific membrane antigen for PET/CT imaging of prostate cancer.
10.7507/1001-5515.201911073
- Author:
Lili PAN
1
;
Xiaoai WU
1
;
Wei DIAO
1
;
Lin LI
1
Author Information
1. Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, P.R.China.
- Publication Type:Journal Article
- Keywords:
positron emission tomography/computed tomography;
prostate cancer;
prostate-specific membrane antigen;
radiopharmaceuticals
- MeSH:
Electrons;
Humans;
Kallikreins;
antagonists & inhibitors;
Male;
Positron Emission Tomography Computed Tomography;
Prostate-Specific Antigen;
antagonists & inhibitors;
Prostatic Neoplasms;
diagnostic imaging;
Radioisotopes;
chemistry
- From:
Journal of Biomedical Engineering
2020;37(2):219-224
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most common tumor of the urinary system, and its mortality rate is second only to lung cancer. With the specific and high expression on the surface of prostate cancer cells, prostate-specific membrane antigen (PSMA) has been an ideal theranostic target of prostate cancer with great clinical significance and research value. Positron emission tomography/computed tomography (PET/CT), a new modality of molecular imaging combining functional metabolic information and anatomical structure, provides high diagnostic performance for cancer detection. This paper mainly reviewed recent progress of PSMA inhibitors labeled by positron-emitting radionuclides for early diagnosis, preoperative staging, response assessment, restaging and metastasis detection of prostate cancer.
